4-(5-Methylnonan-5-yl)pyridine | 1285637-80-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 4-(5-Methylnonan-5-yl)pyridine
• CAS: 1285637-80-0
• 化学式: C₁₅H₂₅N
• 分子量: 219.37
• InChiKey: ULFMZGQOVUCTCO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.8
• 重原子数：
  16
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  、 碘甲烷 在 lithium dihydronaphthylide radical 作用下， 以 四氢呋喃 为溶剂， 反应 16.67h， 以78%的产率得到4-(5-Methylnonan-5-yl)pyridine
  参考文献：
  名称：

  萘二甲酸锂诱导的还原烷基化和芳基和杂芳基取代的二烷基乙腈的添加

  摘要：

  研究了萘锂（LN）诱导的芳基，吡啶基和2-噻吩基取代的二烷基乙腈的还原烷基化/加成反应。在-40°C的THF中用LN处理后，芳基和吡啶基前体均可顺利进行还原性脱氰作用，并且原位生成的碳负离子很容易被卤代烷，酮，醛或什至氧气捕获，从而提供了宽范围带有新建立的季碳的官能化芳族衍生物的制备 为了实现所需的2-噻吩基二烷基乙腈的还原性烷基化反应，需要低得多的温度，例如-100°C。同样在这些底物上，当在-78°C下进行还原烷基化反应时，观察到有趣的开环/ S-烷基化过程，得到1-烷基硫烷基-1,3,4-三烯。 还原烷基化-还原加成-还原脱氰-腈-萘锂-芳基衍生物-杂芳基衍生物-取代的1,3,4-三烯

  DOI：

  10.1055/s-0030-1258301

文献信息

• Compounds and compositions for treating conditions associated with NLRP activity
  申请人：Novartis AG

  公开号：US11370763B2

  公开（公告）日：2022-06-28

  In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured. The variables shown in Formula AA are as defined in the claims. The compounds of formula AA are NLRP3 activity modulators and, as such, can be used in the treatment of metabolic disorders (e.g. Type 2 diabetes, atherosclerosis, obesity or gout), a disease of the central nervous system (e.g. Alzheimer's disease, multiple sclerosis, Amyotrophic Lateral Sclerosis or Parkinson's disease), lung disease (e.g. asthma, COPD or pulmonary idiopathic fibrosis), liver disease (e.g. NASH syndrome, viral hepatitis or cirrhosis), pancreatic disease (e.g. acute pancreatitis or chronic pancreatitis), kidney disease (e.g. acute kidney injury or chronic kidney injury), intestinal disease (e.g. Crohn's disease or Ulcerative Colitis), skin disease (e.g. psoriasis), musculoskeletal disease (e.g. scleroderma), a vessel disorder (e.g. giant cell arteritis), a disorder of the bones (e.g. osteoarthritis, osteoporosis or osteopetrosis disorders), eye disease (e.g. glaucoma or macular degeneration), a disease caused by viral infection (e.g. HIV or AIDS), an autoimmune disease (e.g. Rheumatoid Arthritis, Systemic Lupus Erythematosus or Autoimmune Thyroiditis), cancer or aging.

  在一个方面，以式 AA 的化合物或其药学上可接受的盐为特征。式 AA 中所示变量如权利要求书中所定义。式 AA 的化合物是 NLRP3 活性调节剂，因此可用于治疗代谢性疾病（如 2 型糖尿病、动脉粥样硬化、肥胖或痛风）、中枢神经系统疾病（如阿尔茨海默病、多发性硬化症、多发性脊髓侧索硬化症、多发性硬化症等）。阿尔茨海默病、多发性硬化症、肌萎缩侧索硬化症或帕金森病）、肺部疾病（如哮喘、慢性阻塞性肺病或肺特发性纤维化）、肝脏疾病（如 NASH 综合征、病毒性肝炎或肝硬化）、胰腺疾病（如急性胰腺炎或慢性胰腺炎）、肾脏疾病（如急性肾损伤或慢性肾损伤）。急性肾损伤或慢性肾损伤）、肠道疾病（如克罗恩病或溃疡性结肠炎）、皮肤病（如牛皮癣）、肌肉骨骼疾病（如硬皮病）、血管疾病（如巨细胞动脉炎）、骨骼疾病（如骨关节炎、骨质疏松症、骨质疏松症、骨质疏松症、骨质疏松症、骨质疏松症、骨质疏松症、骨质疏松症、骨质疏松症、骨质疏松症、骨质疏松症、骨质疏松症、骨质疏松症等眼病（如青光眼或黄斑变性）、病毒感染引起的疾病（如艾滋病病毒或艾滋病）、自身免疫性疾病（如类风湿性关节炎、系统性红斑狼疮或自身免疫性甲状腺炎）、癌症或衰老。
• Broad spectrum inhibitors of filoviruses
  申请人：Microbiotix, Inc.

  公开号：US11459308B2

  公开（公告）日：2022-10-04

  The present invention is related to the development of therapeutics and prophylactics for the treatment and/or prevention of filovirus infection in humans and other mammals. A new class of small molecules is disclosed that inhibits the interaction of naturally processed (i.e., proteolytically cleaved) filovirus glycoprotein (GPCL) with its host receptor Niemann-Pick C1 (NPC1) protein and thus block infection of host cells by filoviruses. Also disclosed are methods of using the small molecule inhibitors in the treatment/prevention of filovirus infection.

  本发明涉及治疗和/或预防人类和其他哺乳动物丝状病毒感染的治疗剂和预防剂的开发。本发明公开了一类新的小分子化合物，可抑制天然加工（即蛋白水解）的丝状病毒糖蛋白（GPCL）与其宿主受体 Niemann-Pick C1（NPC1）蛋白的相互作用，从而阻断丝状病毒对宿主细胞的感染。还公开了使用小分子抑制剂治疗/预防丝状病毒感染的方法。
• BROAD SPECTRUM INHIBITORS OF FILOVIRUSES
  申请人：Microbiotix, Inc.

  公开号：US20190292165A1

  公开（公告）日：2019-09-26

  The present invention is related to the development of therapeutics and prophylactics for the treatment and/or prevention of filovirus infection in humans and other mammals. A new class of small molecules is disclosed that inhibits the interaction of naturally processed (i.e., proteolytically cleaved) filovirus glycoprotein (GP CL ) with its host receptor Niemann-Pick C1 (NPC1) protein and thus block infection of host cells by filoviruses. Also disclosed are methods of using the small molecule inhibitors in the treatment/prevention of filovirus infection.
• COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY
  申请人：NOVARTIS INFLAMMASOME RESEARCH, INC.

  公开号：US20210230129A1

  公开（公告）日：2021-07-29

  In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured. The variables shown in Formula AA are as defined in the claims. The compounds of formula AA are NLRP3 activity modulators and, as such, can be used in the treatment of metabolic disorders (e.g. Type 2 diabetes, atherosclerosis, obesity or gout), a disease of the central nervous system (e.g. Alzheimer's disease, multiple sclerosis, Amyotrophic Lateral Sclerosis or Parkinson's disease), lung disease (e.g. asthma, COPD or pulmonary idiopathic fibrosis), liver disease (e.g. NASH syndrome, viral hepatitis or cirrhosis), pancreatic disease (e.g. acute pancreatitis or chronic pancreatitis), kidney disease (e.g. acute kidney injury or chronic kidney injury), intestinal disease (e.g. Crohn's disease or Ulcerative Colitis), skin disease (e.g. psoriasis), musculoskeletal disease (e.g. scleroderma), a vessel disorder (e.g. giant cell arteritis), a disorder of the bones (e.g. osteoarthritis, osteoporosis or osteopetrosis disorders), eye disease (e.g. glaucoma or macular degeneration), a disease caused by viral infection (e.g. HIV or AIDS), an autoimmune disease (e.g. Rheumatoid Arthritis, Systemic Lupus Erythematosus or Autoimmune Thyroiditis), cancer or aging.
• US9783525B2
  申请人：——

  公开号：US9783525B2

  公开（公告）日：2017-10-10